FDA Clears Phase 1 Trial of ARV-110 for Advanced Prostate Cancer
News
The U.S. Food and Drug Administration has signed off on Arvinas‘ first Phase 1 clinical trial to evaluate ARV-110 as a therapy for patients with metastatic castration-resistant prostate cancer (mCRPC). The ... Read more